If approved, TIBSOVO will be the first and only approved targeted therapy for MDS patients with a susceptible IDH1 mutation Submission supported by comprehensive clinical data package, including updated results that demonstrate durable remissions and an acceptable safety profile BOSTON,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.